# GeDiPNet Cluster 65 -- Enriched Pathways -- generated 2026-10-09 07:17:11
# Pathway enrichment: KEGG + Reactome, upper-tail hypergeometric test, Benjamini-Hochberg FDR-corrected. Fold enrichment = (overlap / cluster gene count) / (pathway gene count / universe size). Top 15 pathways per cluster by q-value. See scripts/build_cluster_enrichment.php on gedipnet.bicnirrh.res.in. Data as of: 2026-10-09 03:30:08.
Pathway	Source	Overlap Genes	Overlap Gene Names	Pathway Gene Count	Cluster Gene Count	Fold Enrichment	P-value	FDR Q-value
Pathways in cancer	KEGG	119	BAD, BCL2L11, BRCA2, CASP8, ESR1, FGFR2, MECOM, MMP9, TERT, TP53, ETS1, AKT1	533	1349	1.99	4.947e-14	1.215e-11
Human T-cell leukemia virus 1 infection	KEGG	63	HLA-B, HLA-DQB1, HLA-DRA, MAP3K1, TERT, TP53, ETS1, AKT1, ATM, BCL2L1, BUB1B, CCNA1	224	1349	2.50	2.089e-12	3.942e-10
Gastric cancer	KEGG	47	FGFR2, TERT, TP53, ABCB1, AKT1, APC, AXIN1, BRAF, CCND1, CCNE1, CDKN1B, CDKN2B	150	1349	2.79	2.299e-11	3.549e-9
Prostate cancer	KEGG	36	BAD, FGFR2, MMP9, TP53, AKT1, AR, BRAF, CCND1, CCNE1, CDKN1B, CTNNB1, E2F1	98	1349	3.27	3.199e-11	4.829e-9
Colorectal cancer	KEGG	33	BAD, BCL2L11, TP53, AKT1, APC, AXIN1, BIRC5, BRAF, CCND1, CTNNB1, EGF, EGFR	87	1349	3.38	7.817e-11	1.086e-8
EGFR tyrosine kinase inhibitor resistance	KEGG	31	BAD, BCL2L11, FGFR2, AKT1, BCL2L1, BRAF, EGF, EGFR, HGF, HRAS, IGF1, IGF1R	80	1349	3.45	1.552e-10	2.035e-8
Cell cycle	KEGG	46	TP53, ATM, AURKB, BUB1, BUB1B, CCNA1, CCNB1, CCNB2, CCND1, CCNE1, CDC20, CDC25C	158	1349	2.59	5.842e-10	6.576e-8
Endocrine resistance	KEGG	34	BAD, ESR1, MMP9, TP53, AKT1, BRAF, CCND1, CDK4, CDKN1B, CDKN2A, CDKN2C, E2F1	99	1349	3.06	9.058e-10	9.703e-8
Melanoma	KEGG	28	BAD, TP53, AKT1, BRAF, CCND1, CDK4, CDKN2A, E2F1, EGF, EGFR, FGF19, FGF3	73	1349	3.41	1.574e-9	1.584e-7
Breast cancer	KEGG	43	BRCA2, ESR1, TP53, AKT1, APC, AXIN1, BRAF, CCND1, CDK4, CTNNB1, E2F1, EGF	148	1349	2.59	2.275e-9	2.205e-7
PIP3 activates AKT signaling	Reactome	31	ESR1, FGFR2, AKT1, EGF, EGFR, EREG, FGF19, FGF3, FGF4, FGFR1, HGF, IL1RAP	93	1349	2.97	1.126e-8	9.120e-7
Constitutive Signaling by Aberrant PI3K in Cancer	Reactome	27	ESR1, FGFR2, EGF, EGFR, EREG, FGF19, FGF3, FGF4, FGFR1, HGF, IRS1, IRS2	75	1349	3.21	1.535e-8	1.198e-6
Bladder cancer	KEGG	19	MMP9, TP53, BRAF, CCND1, CDK4, CDKN2A, CXCL8, E2F1, EGF, EGFR, HRAS, KRAS	41	1349	4.13	1.727e-8	1.331e-6
Hepatocellular carcinoma	KEGG	45	BAD, TERT, TP53, ACTB, AKT1, APC, ARID1A, ARID1B, ARID2, AXIN1, BCL2L1, BRAF	170	1349	2.36	2.337e-8	1.737e-6
Pancreatic cancer	KEGG	27	BAD, BRCA2, TP53, AKT1, BCL2L1, BRAF, CCND1, CDK4, CDKN2A, E2F1, EGF, EGFR	77	1349	3.12	2.931e-8	2.133e-6